Cytovance Biologics Launches Standalone Analytical Services to Accelerate Biologics Development

Providing GMP and non-GMP analytical testing for pharmaceutical organizations at every stage of advancement

Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) helping the biopharmaceutical sector, announced the expansion of its analytical solution portfolio with standalone analytical capabilities for biotechnology and pharmaceutical customers. The novel strategies provide access to Cytovance's experienced analytical team and regulatory-ready analytical solutions without needing a production engagement.

Building on more than 20 years of experience helping biologics advancement and production programs, Cytovance is making its analytical expertise available as a standalone service to support sponsors in addressing increasing requirements for outsourced analytical support. Consumer recently engaged Cytovance for standalone analytical technology advancement, transfer, qualification, validation, product characterization, release testing, stability research, and storage while preserving flexibility in their development and production approaches.

"Today's biotechnology companies face increasing pressure to advance programs quickly while managing limited internal resources, evolving regulatory requirements, and increasingly complex development pathways," said Ping Zhang, CEO of Cytovance Biologics. "By expanding our analytical services, we are providing sponsors with access to experienced scientists, robust analytical capabilities, and quality-driven processes that support informed decision-making throughout development. Our goal is to help clients move programs forward efficiently and with confidence."

The expanded analytical services support programs from early-stage advancement through commercialization and are available under both GMP and non-GMP environments. For evolving biotechnology organizations operating with lean teams and limited laboratory infrastructure, Cytovance provides analytical development expertise and platform methodologies that support faster product characterization and development activities. As programs advance, sponsors leverage GMP-compliant testing and stability solutions to support regulatory submissions, technology validation, and profitable readiness.

"Our approach is centered on becoming a strategic analytical partner and an extension of our clients' teams," said Sudha Ankala, Ph.D., PMP, Senior Director of Program Management at Cytovance Biologics. "Whether a sponsor requires a single analytical study, ongoing stability support, or routine GMP testing, we provide scientific expertise, rapid communication, and the flexibility needed to adapt to evolving program requirements and development timelines."

The organization expects demand for U.S.-based analytical services to continue to grow as biologics pipelines increase and organizations seek dependable domestic collaboration. The launch of standalone analytical services further strengthens Cytovance's commitment to offering flexible, science-driven services for biologics developers.

According to Towards Healthcare, the cell and gene therapy bioanalytical testing services market is projected to grow significantly, with estimates indicating the market size will increase from USD 632.55 million in 2026 to approximately USD 1200.62 million by 2035, expanding at a CAGR of 7.38% from 2026 to 2035. Cell therapies have wide applications for managing oncology, autoimmunity, and different disease conditions. CGT bioanalysis supports biodistribution, viral shedding, immunogenicity, and efficacy biomarker testing from discovery to healthcare stages. New modalities like cell and gene therapies have proven to be effective for various clinical indications, especially in rare disease and immuno-oncology.  These testing solutions include a variety of analytical processes intended to assess the safety, effectiveness, and quality of therapeutic products.

About Cytovance

Cytovance Biologics is an established large-molecule CDMO that is huge enough to support customers at every stage and small enough to stay agile, providing programs the care it deserves. For 20 years, Team Cytovance has offered flexibility and ingenuity in a wide range of integrated services, supporting mammalian and microbial-based products on their journey from molecule to commercial manufacturing.

A recent report by Towards Healthcare highlights that the cell and gene therapy bioanalytical testing services market is growing, as cell and gene therapies are hopeful new therapeutic modalities applied in the management of inherited and acquired diseases. These therapies have seen a dynamic renaissance, particularly since the first market approvals of gene therapy products, and have become a region of rapid growth and promise in therapeutic development to tackle unmet medical needs. Cell therapy is the treatment of a disease via the injection, grafting, or implanting of bioengineered cells that elicit a specific healthcare effect. This presents an important departure from traditional medical care treatment, as the therapeutic is no longer a single or collection of molecules but is an entire cell, which drives the growth of the market.